Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019
March 31, 2020 17:27 ET
|
Ritter Pharmaceuticals, Inc.
Definitive merger agreement with Qualigen, Inc. announced in January 2020 LOS ANGELES, March 31, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”,...
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
January 21, 2020 09:15 ET
|
Ritter Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...
Ritter Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2019 and Provides Business Update
November 13, 2019 19:35 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of therapeutic products that modulate the gut...
Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives
October 07, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that...
Ritter Pharmaceuticals Reports Top-Line Results from its Liberatus Phase 3 Trial of RP-G28 for Lactose Intolerance
September 12, 2019 16:15 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Sept. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that...
Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2019 and Provides a Corporate Update
August 14, 2019 17:11 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals Appoints Esteemed Gastroenterologist Anthony J. Lembo, M.D. to its Medical Advisory Board
August 13, 2019 09:15 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals Provides Highlights from Lactose Intolerance Market Research Call
August 08, 2019 14:16 ET
|
Ritter Pharmaceuticals, Inc.
Market research indicates an unmet need for better lactose intolerance treatments and interest from both patients and physicians in the RP-G28 drug profile LOS ANGELES, Aug. 08, 2019 (GLOBE...
Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings
July 31, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
Daniel P. Lundberg, Consultant to Ritter Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals to address market opportunity for Phase 3, lactose intolerance drug candidate RP-G28...
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
July 11, 2019 17:28 ET
|
Ritter Pharmaceuticals, Inc.
Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES, July 11, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the...